This is a type of imaging test used to look for cancer. It uses special radioactive antibodies attached to a camera. The camera takes pictures of the cancer cells, showing where they are located in the body.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Radioimmunodetection, also called immunoscintigraphy, is a nuclear medicine scan that uses an antibody to find cancer. Antibodies are proteins that attach to one specific target. In this test, an antibody chosen because it sticks to a marker on certain cancer cells is joined to a small amount of a radioactive substance (a tracer) and injected into a vein. Over the following days the antibody collects where its target is, and a scanner that detects radiation shows where in the body that is. The best-known example in the United States was capromab pendetide (ProstaScint), an antibody scan for prostate cancer. It was used to look for spread to lymph nodes in men with newly diagnosed, high-risk prostate cancer, and to look for cancer returning after the prostate was removed. Its images were hard to read accurately, and it is now rarely used. For prostate cancer it has largely been replaced by PSMA PET scans. These use positron emission tomography (PET) to find prostate-specific membrane antigen (PSMA), a protein abundant on prostate cancer cells, with small molecules rather than antibodies, and give sharper results within hours. Today, antibody-based scanning mostly takes the form of immuno-PET, which pairs an antibody with a PET scanner. It is used mainly in research studies, for example to show whether a tumor carries the target of an antibody treatment or to tell whether a kidney mass is clear cell renal cell carcinoma, the most common type of kidney cancer. If you are offered this test, it is most likely as part of a clinical trial or at a specialized cancer center, and the reason it was chosen over a standard CT, MRI or PET scan is worth asking about.
The care team explains which antibody and tracer will be used, what the scan is meant to answer, and how many visits it will take. Because the antibody needs days to reach its target, plan for an injection visit and at least one return visit for imaging. Tell the team if you are pregnant, might be pregnant or are breastfeeding, since the test involves radiation. Mention any past allergic reaction to an antibody medicine or to a previous scan of this kind, and any earlier treatment or test that used a mouse-derived antibody, because the body may have formed antibodies against it. Some protocols ask you to take a laxative or have an enema before imaging so that tracer passing through the bowel does not blur the pictures. Instructions differ between agents and centers, so follow the specific ones you are given.
The tracer-labeled antibody is given through an IV, a thin tube placed in a vein in the arm, usually over several minutes. Staff keep an eye on you during and after the injection in case of a reaction. A first set of pictures is sometimes taken soon afterward. The main images are taken days later, once the antibody has cleared from the blood and settled where its target is. With the older prostate scan this was three to five days after the injection, and immuno-PET studies have imaged anywhere from the day of injection to about ten days afterward. Each imaging session involves lying still on a table while a gamma camera, a SPECT scanner (single-photon emission computed tomography, which builds 3D pictures from the camera's readings) or a PET scanner moves around you. Sessions are painless and often last from under an hour to a couple of hours, sometimes with a CT scan at the same time to show anatomy.
There is no recovery period in the usual sense. Most people return to normal activities right away, and you may be encouraged to drink fluids. Because the tracer stays in the body for days, some centers give short-term precautions, such as limiting close contact with young children or anyone who is pregnant. Follow the specific advice your center gives, since it depends on the tracer used. A nuclear medicine doctor reads the images and sends a report to your specialist, which usually takes some days after the last session. The findings are rarely the final word. They are typically combined with other scans, blood tests or a biopsy before treatment decisions are made.
Most people have no side effects. With the older prostate scan, about 4 in 100 people had a reaction, mostly mild and short-lived, such as a change in blood pressure, itching, rash, fever, headache or soreness where the needle went in. Allergic reactions, including severe ones, are possible with antibodies made from mouse proteins, which is why the injection is given where staff can treat a reaction. Tell staff right away about itching, rash, flushing or trouble breathing during or soon after the injection. Mouse-derived antibodies can lead the immune system to make its own antibodies against them, known as human anti-mouse antibodies or HAMA. These can make some later blood tests, including PSA (the prostate-specific antigen test used to monitor prostate cancer) and blood levels of digoxin (Lanoxin, a heart failure and heart rhythm medicine whose level is checked to avoid overdose), read falsely high. If you have had this kind of scan, tell your doctors and the laboratory so they can use a test that avoids the problem. These antibodies can also make a repeat antibody scan or antibody treatment less reliable. The scan involves radiation. Antibody tracers stay in the body longer than the tracers used for most PET scans, so the dose tends to be higher, although teams use the smallest amount that gives useful images. Finally, the results can be wrong in both directions: a scan can light up where there is no cancer or miss cancer that is present. That is why findings are usually confirmed before they change treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Radioimmunodetection, what to expect, or ask the community a question.